Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.71 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.60 |
| ▸ | CNR1 | P21554 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5520639 | 1.00 | SLC6A5 (0.71) | SLC6A5EPHX2CNR1ALDH1A1HPGD | |
| SCHEMBL5520632 | 1.00 | SLC6A5 (0.71) | SLC6A5EPHX2CNR1ALDH1A1HPGD | |
| SCHEMBL3505712 | 1.00 | SLC6A5 (0.71) | SLC6A5EPHX2CNR1ALDH1A1HPGD | |
| SCHEMBL5529570 | 0.93 | EPHX2 (0.68) | SLC6A5EPHX2CNR1ALDH1A1HPGD | |
| SCHEMBL5529572 | 0.93 | EPHX2 (0.68) | SLC6A5EPHX2CNR1ALDH1A1HPGD | |
| SCHEMBL18157870 | 0.93 | EPHX2 (0.68) | SLC6A5EPHX2CNR1ALDH1A1HPGD | |
| SCHEMBL8353089 | 0.92 | DNM1 (0.66) | SLC6A5EPHX2CNR1DNM1FAAH | |
| SCHEMBL9452842 | 0.92 | DNM1 (0.66) | SLC6A5EPHX2CNR1DNM1FAAH | |
| SCHEMBL13114479 | 0.90 | EPHX2 (0.65) | SLC6A5EPHX2CNR1ALDH1A1HPGD | |
| SCHEMBL540380 | 0.90 | SLC6A5 (0.58) | SLC6A5EPHX2CNR1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414322-B1 | POLYAMINE DERIVATIVES | EGEN INC (US) | 2022-09-14 | — | — | EP | disclosed |
| US-9254334-B2 | Polyamine derivatives | CLSN LABORATORIES, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150099000-A1 | Polyamine Derivatives | CLSN LABORATORIES, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-8932638-B2 | Polyamine derivatives | CLSN LABORATORIES, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8900621-B2 | Polyamine derivatives | CLSN LABORATORIES, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140050775-A1 | Polyamine Derivatives | EGEN, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20130251809-A1 | Polyamine Derivatives | EGEN, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8460696-B2 | Polyamine derivatives | EGEN, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2414322-A2 | POLYAMINE DERIVATIVES | Egen, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100260817-A1 | Polyamine Derivatives | EGEN, INC. | 2010-10-14 | — | — | US | disclosed |
| EP-1513538-A4 | NOVEL METHODS FOR THE DELIVERY OF POLYNUCLEOTIDES TO CELLS | MIRUS BIO CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1513538-A2 | NOVEL METHODS FOR THE DELIVERY OF POLYNUCLEOTIDES TO CELLS | Mirus Corporation (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030235916-A1 | Novel methods for the delivery of polynucleotides to cells | ROCHE MADISON INC. | 2003-12-25 | — | — | US | disclosed |
| WO-2003106636-A2 | NOVEL METHODS FOR THE DELIVERY OF POLYNUCLEOTIDES TO CELLS | MIRUS CORPORATION (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130251809-A1 | Polyamine Derivatives | SRM, SMS, SGMS2 | SLC6A5 2185/4885EPHX2 2183/4885CNR1 3545/4885 |
| US-20150099000-A1 | Polyamine Derivatives | SRM, SMS, SGMS2 | SLC6A5 2185/4885EPHX2 2183/4885CNR1 3545/4885 |
| US-20100260817-A1 | Polyamine Derivatives | SRM, SMS, SGMS2 | SLC6A5 2185/4885EPHX2 2183/4885CNR1 3545/4885 |
| US-20140050775-A1 | Polyamine Derivatives | SRM, SMS, SGMS2 | SLC6A5 2185/4885EPHX2 2183/4885CNR1 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.